The global clinical chemistry and immunodiagnostics market is being transformed by high-growth forces that extend well beyond AI. The GLP-1 drug wave is creating entirely new cardiometabolic monitoring requirements. FDA-cleared blood-based Alzheimer's biomarker tests are enabling primary care diagnosis for the first time. Lp(a) assays are emerging as a standard cardiovascular risk tool. And infrastructure expansion across Asia-Pacific, Latin America, and the Middle East is driving first-time platform placements at unprecedented scale.

The report, based on primary research, provides unique information and analysis not available from any other source, including:

- 2025 Supplier Shares by Country
- 2025-2030 Volume and Sales Segment Forecasts for over 120 Abused Drugs, Endocrine, Immunoprotein, Routine Chemistry, Special Chemistry and TDM Tests
- Supplier Strategies and SWOT Analysis
- Emerging Technologies
- Opportunities for New Analyzers and Consumables
- Market Challenges and Risks

High-Growth Opportunities Assessed in This Report

- AI Impact -- automated result interpretation, reflex testing algorithms, quality control automation, and laboratory workflow optimization
- GLP-1 Drug Monitoring -- cardiometabolic biomarker demand surge driven by semaglutide, tirzepatide, and next-generation obesity therapeutics
- Alzheimer's Blood Biomarkers -- FDA-cleared plasma pTau181 and amyloid tests enabling primary care screening with Fujirebio Lumipulse and Roche Elecsys
- Cardiovascular Risk Stratification -- Lp(a) assays, high-sensitivity troponin, NT-proBNP, and emerging inflammatory biomarkers
- Emerging Market Infrastructure -- Asia-Pacific, Latin America, Middle East, and Africa expanding hospital laboratory capacity and driving new analyzer placements
- Point-of-Care Expansion -- high-sensitivity cardiac troponin, HbA1c, and cardiometabolic panels moving to near-patient testing settings
- Total Laboratory Automation -- integrated chemistry and immunoassay platforms driving productivity gains and workflow consolidation
- Managed Service Contracts -- reagent rental and equipment-as-a-service models reshaping the competitive landscape
- Special Chemistry and TDM Growth -- therapeutic drug monitoring expansion driven by biologics, immunosuppressants, and oncology agents

This 98-country report from LeadingMarketResearch.com is available by region, country, market segment, section, individual test and can be customized to specific information needs and budget.

The report provides a granular strategic analysis of over 120 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both centralized (hospitals, commercial laboratories), and POC/decentralized locations. The report explores future market trends; provides specimen, test volume and sales segment forecasts; estimates sales and market shares of key suppliers in major countries; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities for reagent and instrument suppliers.

To fit your research budget and receive sections of this report or specific data on geographic regions, countries, markets, companies, technologies and products, select the exact information you need from our Clinical Chemistry Database.

Rationale

Clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.

Geographic Regions and Countries

Africa

Algeria, Egypt, Ghana, Kenya, Morocco, Nigeria, South Africa

Asia-Pacific

Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Turkey, Vietnam

Europe

Albania, Austria, Belarus, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine

Latin America

Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela

Middle East

Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates

North America

Canada, Mexico, USA

Global Market Overview

- Estimates of facilities performing clinical chemistry and immunodiagnostic tests in major countries.

- Test volume and sales projections.

Market Segmentation Analysis

- Comprehensive review of the market dynamics, trends, structure, size, growth, and key suppliers.

- Test volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays.

Individual Tests Analyzed in the Report

Clinical Chemistry

Albumin, Alkaline Phosphatase, ALT/SGPT, Ammonia, Amylase, Apolipoprotein A-1, Apolipoprotein B, AST/SGOT, Beta-Hydroxybutyrate, Bilirubin (Direct), Bilirubin (Total), BNP, BUN (Blood Urea Nitrogen), Calcitonin, Calcium, Carbon Dioxide/Bicarbonate, Cardio hs CRP, Chloride, Cholesterol, Cholinesterase, Creatine Kinase (CK), CK-MB, Creatinine, CRP, Cystatin C, Ferritin, Fructosamine, GGT, Glucose, HDL Cholesterol, Homocysteine, hs-CRP, Insulin, Iron, Iron (Total Binding Capacity), Iron (Unsaturated Binding Capacity), LDH, LDL Cholesterol, LDL Cholesterol Direct, Lipase, Lipoprotein a, Magnesium, Microalbumin, Myoglobin, NT-proBNP, Phosphorus, Potassium, Sodium, ST2, Total Protein, Transferrin, Triglycerides, Troponin, Uric Acid

Therapeutic Drug Monitoring (TDM)

Amikacin, Apixaban, Argatroban, Betrixaban, Carbamazepine, Cyclosporin, Dabigatran, Digoxin, Edoxaban, Everolimus, Fluindione, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Rivaroxaban, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin, Warfarin

Endocrine Function

Cortisol, Estradiol, FSH, HCG, Gastrin, Growth Hormone/IGF-1, LH, Progesterone, PTH/IO PTH, Prolactin, T3, T3 Free, T3 Uptake, T4, T4 Free, TBG, Testosterone, Thyroglobulin Ab, TPO Ab, TSH

Tumor Markers and Special Chemistry

AFP, CA 15-3/27-29, CA 19-9, CEA, Ferritin, Follate (Folic Acid), Glycosylated Hemoglobin, HCG, 25-Hydroxy Vitamin D2 and D3, Occult Blood, PAP, PSA, Thyroglobulin, Vitamin B-12

Immunoproteins

C3, C4, Free Light Chains, Haptoglobin, IgA, IgE Specific, IgE Total, IgG, IgM, Immunofixation, Prealbumin, Protein Electrophoresis

Drugs of Abuse

Amphetamines, Barbiturates, Benzodiazepines, Cannabinoids/Marijuana, Cocaine, LSD, Methadone, Methaqualone, Opiates, Phencyclidine (PCP), Propoxyphene, Tricyclic Antidepressants

Current and Emerging Products

- Analysis of current and emerging clinical chemistry and immunodiagnostic tests.

- Review of current instrumentation technologies, and feature comparison of high-, medium-, and low-volume/POC analyzers.

Technology Review

- Assessment of current and emerging technologies, and their potential market applications.

- Companies developing or marketing new technologies and products by test.

Strategic Recommendations

- New product development opportunities with significant market appeal.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Competitive Assessments

- Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.

- The companies analyzed in the report include:

- Abbott Laboratories
- Agilent Technologies
- Beckman Coulter/Danaher
- bioMerieux
- Bio-Rad
- DiaSorin
- Eiken Chemical
- Fujifilm Wako
- Fujirebio
- Grifols
- Instrumentation Laboratory/Werfen
- Kyowa Medex
- PerkinElmer
- Quest Diagnostics
- QuidelOrtho
- Roche
- Siemens Healthineers
- Sysmex
- Thermo Fisher
- Tosoh

Related Clinical Chemistry and Immunodiagnostics Market Reports

Related Diagnostics Market Reports